Trial Profile
A Feasibility Study of Gemcitabin and Bevacizumab in patients with Platinum-Resistant Recurrent Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
Status:
Recruiting
Phase of Trial:
Phase II
Latest Information Update: 15 Jun 2017
Price :
$35
*
At a glance
- Drugs Bevacizumab (Primary) ; Gemcitabine (Primary)
- Indications Fallopian tube cancer; Ovarian cancer; Peritoneal cancer
- Focus Therapeutic Use
- Acronyms G-Bev
- 06 Jun 2017 Results (n=15) presented at the 53rd Annual Meeting of the American Society of Clinical Oncology
- 03 Mar 2015 New trial record